University of Kentucky
UKnowledge

Markey Cancer Center Faculty Publications

Markey Cancer Center

12-1-2016

Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis

Gurprataap S. Sandhu
University of Pittsburgh

Sebhat Erqou
University of Pittsburgh

Heidi Patterson
University of Pittsburgh

Aju Mathew
University of Kentucky, aju.mathew@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/markey_facpub

Part of the [International and Area Studies Commons](#), and the [Oncology Commons](#)

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation

Sandhu, Gurprataap S.; Erqou, Sebhat; Patterson, Heidi; and Mathew, Aju, "Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis" (2016). *Markey Cancer Center Faculty Publications*. 100.

https://uknowledge.uky.edu/markey_facpub/100

This Review is brought to you for free and open access by the Markey Cancer Center at UKnowledge. It has been accepted for inclusion in Markey Cancer Center Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis

Digital Object Identifier (DOI)

<https://doi.org/10.1200/JGO.2016.005397>

Notes/Citation Information

Published in *Journal of Global Oncology*, v. 2, issue 6, p. 412-421.

© 2016 by American Society of Clinical Oncology

Licensed under the [Creative Commons Attribution 4.0 License](#).

Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis

abstract

Purpose There is considerable variation in prevalence rates of triple-negative breast cancer (TNBC) reported by various studies from India. We performed a systematic review and literature-based meta-analysis of these studies.

Methods We searched databases of Medline, Scopus, EMBASE, and Web of Science for studies that reported on the prevalence of TNBC in India that were published between January 1, 1999, and December 31, 2015. We extracted relevant information from each study by using a standardized form. We pooled study-specific estimates by using random-effects meta-analysis to provide summary estimates. We explored sources of heterogeneity by using subgroup analyses and metaregression.

Results Data were obtained from 17 studies that involved 7,237 patients with breast cancer. Overall combined prevalence of TNBC was 31% (95% CI, 27% to 35%). There was substantial heterogeneity across the studies (I^2 of 91% [95% CI, 88% to 94%]; $P < .001$) that was not explained by available study level characteristics, including study location, definition of human epidermal growth factor receptor 2 or estrogen receptor, mean age of participants, proportion of patients with premenopausal cancer, grade 3 disease, or tumor size > 5 cm. Overall combined prevalence of hormone receptor–positive and human epidermal growth factor receptor 2–positive breast cancer was 48% (95% CI, 42% to 54%) and 27% (95% CI, 24% to 31%), respectively. There was no evidence of publication bias.

Conclusion Prevalence of TNBC in India is considerably higher compared with that seen in Western populations. As many as one in three women with breast cancer could have triple-negative disease. This finding has significant clinical relevance as it may contribute to poor outcomes in patients with breast cancer in India. Additional research is needed to understand the determinants of TNBC in India.

J Glob Oncol 2. © 2016 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License

Gurprataap S. Sandhu
Sebhat Erqou
Heidi Patterson
Aju Mathew

Gurprataap S. Sandhu, Sebhat Erqou, and Heidi Patterson, University of Pittsburgh Medical Center, Pittsburgh, PA; and Aju Mathew, Markey Cancer Center, University of Kentucky, Lexington, KY.

Authors' disclosures of potential conflicts of interest and contributions are found at the end of this article.

Corresponding author: Aju Mathew, MD, MPhil, University of Kentucky, 800 Rose St, CC447, Lexington, KY 40536; e-mail: aju.mathew@uky.edu.

INTRODUCTION

Breast cancer is a heterogeneous disease with different biologic subtypes that are recognized by gene expression profiling studies. Clinically, these subtypes are characterized on the basis of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Triple-negative breast cancer (TNBC) is an aggressive subtype that is defined by lack of expression of ER and PR as well as absence of overexpressed or amplified HER2.¹ TNBC accounts for approximately 12% to 17% of all invasive breast cancers in Western populations.¹ TNBC occurs more frequently in younger women and is associated with higher histologic grade and more advanced disease.^{1,2} In North America, it is more frequently seen in women of African American ethnicity compared with other ethnic groups.²⁻⁵

Breast cancer is the most common cancer in India.⁶ For example, in 2012, it is estimated that approximately 145,000 new patients were diagnosed with breast cancer in India, and nearly 70,000 women died of the disease.⁷ Age-standardized 5-year breast cancer survival for Indian women diagnosed with breast cancer is 60% compared with $> 80\%$ in Western countries.⁸ Whereas breast cancer incidence seems to be increasing in the country, epidemiology of the disease is inadequately studied.⁹ Prevalence of TNBC in India is reported to be higher than that observed in Western populations; however, there is considerable variation in prevalence rates reported by studies from the region. It is important to obtain a reliable summary estimate of the prevalence of TNBC in India to address the growing burden of breast cancer in the country. Hence, we conducted a systematic review and

literature-based meta-analysis of studies that reported on the prevalence of TNBC in India.

METHODS

Search Strategy

Studies that reported on the prevalence of TNBC in India that were published between January 1, 1999, and December 31, 2015, were identified by using Medline, Scopus, EMBASE, and Web of Science databases (performed by G.S.S. and H.P.). Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed for article search and reporting. Computer-based search used combinations of the following medical subject headings and keywords: triple negative, breast cancer, and India.

Study Eligibility

We included studies in the meta-analysis if the following criteria were met: provided data on patients with breast cancer in India and described prevalence of triple-negative tumor subtype in the study population. We excluded studies that were comprised of patients with inflammatory breast cancer.

Data Extraction

Two investigators (G.S.S. and A.M.) independently screened all identified titles and abstracts from the search results. We scanned the reference lists of articles for additional articles. Full texts of screened articles were reviewed by G.S.S. and A.M. for inclusion criteria. Disagreements were resolved by consensus. Study selection process and flow diagram for identifying studies is detailed in Figure 1. We extracted relevant information from each study by using a standardized form, which was designed before implementation of the search strategy. The following information was extracted from each article by G.S.S. and A.M.: study design, region, publication year, study year, mean age, stage and grade distribution, receptor status, proportion of patients with ductal histology, proportion of patients with axillary lymph node involvement, proportion of patients who were premenopausal, and method of ER, PR, and HER2 assessment.

Definitions of ER, PR, and HER2

Level of ER is expressed as a product of the percentage of epithelial cells stained and intensity of staining through immunohistochemistry (IHC). Historically, the cutoff value of ER-positive disease was defined as nuclear staining of $\geq 10\%$ of the epithelial component of the tumor; however, in 2010 ASCO lowered the IHC cutoff for determining

ER-positive status from the previous value of 10% to 1% of stained cells.¹⁰ This was based on the finding that even tumors weakly staining in 1% to 10% of cells demonstrated objective clinical benefit from treatment with tamoxifen.¹¹ We extracted data on definitions of ER and PR positivity ($\geq 1\%$ or $\geq 10\%$ or not reported).

With regard to HER2 testing, ASCO released an algorithm that defined positive, equivocal, and negative values for both HER2 protein expression and gene amplification. A positive HER2 result is IHC staining of 3+ (uniform, intense membrane staining of $> 30\%$ of invasive tumor cells), a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus, or a FISH ratio (HER2 gene signals to chromosome 17 signals) of more than 2.2. A negative result is an IHC staining of 0 or 1+, a FISH result of fewer than 4.0 HER2 gene copies per nucleus, or a FISH ratio of less than 1.8.¹² Equivocal results (IHC staining of 2+) require additional testing for final classification. We extracted data on HER2 assessment method; studies that considered an IHC score of 2+ and 3+ as positive for HER2, studies that considered an IHC score of 3+ alone as positive for HER2, studies that used FISH test in patients who had 2+ score by IHC, and studies that did not disclose the method of checking HER2 status.

Only studies that reported on all three receptors (ER, PR, HER2) or those that reported on the proportion of TNBC were included in analyses. In some studies, more patients had data on ER or PR status than on HER2. Hence, in those studies, denominators were changed accordingly to provide an accurate assessment of the prevalence of hormone receptor (HR)-positive disease (defined as ER-positive and/or PR-positive), HER2-positive disease, or TNBC.

Assessment of Study Quality

We used STROBE statement guidelines to assess quality of selected studies.¹³ One point each was given if the study described the setting and study participants, reported descriptive data, provided detailed outcome data, and discussed limitations, for a maximum score of 5 and a minimum of zero. We performed subgroup analysis stratified by study quality score of ≥ 4 versus < 4 .

Statistical Analysis

Standard errors for study-specific prevalence estimates were determined from the point estimate and appropriate denominators, assuming a binomial distribution. To obtain an overall summary estimate of prevalence across studies, we pooled

Fig 1 –

Flow diagram for identifying studies for assessment of prevalence of triple-negative breast cancer in India.

study-specific estimates by using a random-effects model meta-analysis. We also performed a fixed-effect model meta-analysis for comparison. Between-study heterogeneity was quantified by using I^2 statistics. The I^2 statistic estimates percentage of total variation across studies that are the result of true between-study differences rather than chance. We explored sources of heterogeneity by using subgroup analyses and metaregression. We assessed publication bias by using funnel plot symmetry and Egger regression intercept. All analyses were performed using STATA software (v13; STATA, College Station, TX; Computing Resource Center, Santa Monica, CA). Statistical tests were two-sided, and $P < .05$ was considered statistically significant.

RESULTS

Study Characteristics

Seventeen cross-sectional studies that involving 7,237 patients with breast cancer were included in this review (Table 1).¹⁴⁻³⁰ Mean age of patients ranged from 43 to 55 years across studies, with a weighted average of age 50 years. Proportion of patients who were premenopausal ranged from 27% to 67% across studies, with a weighted average of 41%. Proportion of patients with grade 3 disease ranged from 16% to 75%, with a weighted average of 57%; corresponding figures for patients with tumor size > 5 cm were 3% to 65% (weighted average,

24%) and those for patients with positive axillary lymph nodes were 39% to 90% (weighted average, 57%). Prevalence estimates of HR-positive disease, HER2-positive disease, and TNBC in each of the included studies are reported in Table 1.

Prevalence of TNBC

Overall combined prevalence of TNBC in the random-effects model meta-analysis was 31% (95% CI, 27% to 35%). Pooled estimate from the fixed-effect model meta-analyses was comparable (Fig 2). There was substantial heterogeneity across the studies (I^2 of 91.2% [95% CI, 88% to 94%]; $P < .001$). Sources of heterogeneity were explored by several study-level characteristics, as described in Prevalence of TNBC by Study-level Characteristics. Overall combined prevalence of HR-positive breast cancer was 48% (95% CI, 42% to 54%; Fig 3), and overall combined prevalence of HER2-positive breast cancer was 27% (95% CI, 24% to 31%; Fig 4).

Prevalence of TNBC by Study-Level Characteristics

In an attempt to explain heterogeneity, we performed subgroup analysis and metaregression by using several study-level characteristics (Fig 5). Meta-analysis included four studies each from the north, east, and west of the country and five studies

Table 1 – Study Characteristics of 17 Cross-Sectional Studies Included in the Meta-Analysis, and Prevalence of HR-Positive Disease, HER2-Positive Disease, and TNBC in These Studies

Source	Study Time Period	No.	Mean Age, Years	Ductal Histology, %*	Tumor Size > 5 cm, %*	Grade 3 Disease, %*	Positive Nodes, %*	Premenopausal, %*	HR Definition†	HER2 Definition†	HR-Positive, %§	HER2-Positive, %§	TNBC, %§
North													
Verma et al, 2012 ¹⁴	2008-2009	100	53.3	91	3	19	49	NR	≥ 1%	3+	55	36	17
Nigam et al, 2014 ¹⁵	2004-2011	142	49	81.4	NR	NR	66.4	45.4	NR	3+	60.6	26.1	39.4
Nabi et al, 2015 ¹⁶	2009-2013	180	50.5	87.2	16.6	43.3	62.7	NR	≥ 1%	3+	47.7	20	34.4
Doval et al, 2015 ¹⁷	2008-2011	1,284	52.1	94.7	NR	44.4	52.9	41.9	≥ 1%	3+¶	62.2	23	23.8
East													
Sen et al, 2012 ¹⁸	2008	72	43	83.3	29.1	58.3	58.3	54.1	≥ 10%	2+, 3+	36.1	36.1	27.8
Nandi et al, 2014 ¹⁹	2011-2012	135	52	88.1	37.8	58.5	38.5	NR	NR	NR	63.7	33.3	13.3
Jana et al, 2014 ²⁰	2007-2008	242	54.6	NR	52.1	69.8	89.7	27.3	NR	NR	30.2	27.3	46.7
Sharma et al, 2014 ²¹	2010-2013	972	46.1	95.8	24.8	63	54.6	NR	≥ 1%	3+	39.5	22.1	31.9
West													
Singh et al, 2014 ²²	2009-2010	82	50	94	NR	NR	47.6	NR	NR	NR	44.6	34.2	34.1
Akhtar et al, 2015 ²³	2012-2014	85	50	NR	64.7	43.5	66	41.2	≥ 1%	3+	NR	NR	43.5
Mane et al, 2015 ²⁴	2007-2012	521	47	NR	26.7	NR	NR	37.8	≥ 10%	2+, 3+	58.6	30.7	25.3
Ghosh et al, 2011 ²⁵	2008	1,922	49	95.4	NR	75.4	NR	NR	≥ 1%	3+	51.2	17.4	31
South													
Zubeda et al, 2013 ²⁶	2001-2007	300	50	84	NR	NR	NR	NR	≥ 10%	2+, 3+	27	35.7	46
Pathayaket al, 2015 ²⁷	2001-2010	352	50.7	95.3	10.9	35.2	65.4	NR	≥ 1%	2+, 3+	47.6	32.7	22.7
Rao et al, 2013 ²⁸	2009-2011	126	NR	67.4	19.8	15.9	47.6	67.4	≥ 1%	3+	36.5	2.4	50
Amboise et al, 2011 ²⁹	2009-2010	321	53.8	96.3	7.8	33.3	58.2	39.3	≥ 10%	2+, 3+	59.2	27.1	25.2
Lakshmaiah et al, 2014 ³⁰	2012-2013	322	NR	NR	NR	NR	NR	NR	≥ 1%	3+	NR	NR	26.1

Abbreviation: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NR, not reported; TNBC, triple-negative breast cancer.

*Proportion of participants with disease.

†HR-positive defined as ≥ 1% cells staining versus ≥ 10% cells staining.

‡HER2-positive status defined as immunohistochemistry staining 3+ only versus both 2+ and 3+.

§Prevalence of disease in study population.

¶HER2 fluorescence in situ hybridization testing performed for 2+ by immunohistochemistry.

||No. of patients was 2,001, of which 79 did not have HER2 test results.

Fig 2 –

Prevalence of triple-negative breast cancer across 17 studies in India. E, east; N, north; S, south; W, west.

from the south. We found no significant difference in prevalence of TNBC by region. Overall prevalence of TNBC in the north, south, east, and west of the country was 28%, 34%, 30%, and 31%, respectively. Heterogeneity in overall prevalence of TNBC was not explained by other available study-level characteristics, such as mean age of participants or

proportion of patients who were premenopausal, had grade 3 disease, or had tumor size > 5 cm.

Definition of ER, PR, and HER2

Definition of HR and HER2 was variable across studies (Table 1). Nine studies defined HR-

Fig 3 –

Prevalence of hormone receptor-positive breast cancer across 17 studies in India. E, east; N, north; S, south; W, west.

Fig 4 –

Prevalence of human epidermal growth factor receptor 2–positive breast cancer across 17 studies in India. E, east; N, north; S, south; W, west.

positive as ER and PR $\geq 1\%$ and four studies defined HR-positive as ER and PR $\geq 10\%$, whereas four studies did not describe the definition of HR. Nine studies defined HER2-positive status as only 3+ by IHC (Doval et al¹⁷ used FISH test to classify equivocal cases and is therefore included in the 3+ group) and five studies included 2+ as positive, whereas three studies did not describe the definition of HER2. We did not find significant difference in pooled estimates subgrouped by different definitions for HR and HER2 (Fig 5).

Study Quality

One study scored the maximum score of 5, 11 studies scored 4, four studies scored 3, and one study scored 2 on assessment of study quality. Lower quality studies (study quality score < 4) had a tendency to report higher prevalence of TNBC compared with higher quality studies (score ≥ 4); 38% [95% CI, 27% to 48%] versus 29% [95% CI, 25% to 33%], respectively, although confidence intervals overlap ($P = .12$; Fig 5).

Assessment of Publication Bias

There was no evidence of publication bias by visual inspection of funnel plot or Egger test for bias ($P = .24$; Appendix Fig A1). Furthermore, pooled estimate from larger-sized studies ($N \geq 250$), which

are less likely to be subjected to publication bias, with that from smaller-sized studies ($N < 250$) were comparable (29% [95% CI, 25% to 32%] versus 34% [95% CI, 25% to 43%]; $P = .34$; Fig 4).

Sensitivity Analysis

Rao et al²⁸ described a low prevalence of HER2-positive disease (2.4%; $n = 126$). Prevalence of TNBC in this study was 50%. Such a low rate of HER2-positive disease has not been reported from India or elsewhere; however, a sensitivity analysis performed after omitting data from the study yielded results that were similar to the main analyses.

DISCUSSION

To our knowledge, this systematic review and meta-analysis of 17 cross-sectional studies that involved 7,237 patients with breast cancer is the most comprehensive analysis on prevalence of TNBC in India. Prevalence of TNBC in India ranged from 27% to 35% across studies, with a summary estimate of 31%. This is comparable to the prevalence seen in African American women and is more than twice the rate seen in white women.^{5,31-34} Our study also found a higher prevalence of premenopausal breast cancer, grade 3 disease, and larger tumor size, all of which are associated with triple-negative disease.¹⁻³ Because TNBC is known to be more aggressive than other breast cancer subtypes, higher prevalence

Fig 5 –

Prevalence of triple negative breast cancer by various study characteristics. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.

of TNBC could be a contributing factor to the high fatality rate of patients with breast cancer in India.

We explored sources of heterogeneity through subgroup analyses by using study-level characteristics that are known to be associated with a higher prevalence of TNBC, but results were not statistically significant. We also analyzed data on the basis of study location and found similar prevalence rates for TNBC in all four regions in India. We also found that differences in definitions of HR and HER2 positivity did not influence study results.

One limitation of the present meta-analysis is the presence of substantial heterogeneity across the contributing studies that is unexplained by available study-level characteristics; however, similarity of findings from pooled estimates from random-effects and fixed-effect models is reassuring. Furthermore, pooled estimates from the small- and larger-sized studies were comparable. India is a vast country with significant variations in linguistic, geographic, dietary, cultural, and health care-associated practices; therefore, one can postulate the presence of considerable inherent heterogeneity at state level that was not captured by regional compartmentalization. Second, we did not incorporate quality scores into meta-analysis weights. An analysis by study quality suggested a higher prevalence of TNBC in lower-quality studies; however,

difference in prevalence rates by study quality was not statistically significant. Third, the contributing study results are subjected to local laboratory standards and practices. Fourth, primary data are obtained from studies that were conducted at various tertiary-level hospitals, which could result in an inherent selection bias as a result of the possibility that patients who have more advanced disease could be selectively referred to such institutions. However, most cancer care in India occurs in tertiary-level institutions, and, therefore, we do not think the actual prevalence rate will be significantly different from that identified in our meta-analysis. Finally, several potential risk factors, such as obesity, parity, and socioeconomic factors, have not been described in the studies that are included in this meta-analysis.

Multiple factors may account for higher prevalence of TNBC reported by studies conducted among Indian patients with breast cancer. The early age of onset of breast cancer; lifestyle factors, such as diet and obesity; reproductive factors, such as multiparity; socioeconomic status; and screening behaviors may be hypothesized as probable etiology.^{2,3} Another important factor could be a potential genetic susceptibility of Indians to TNBC. More focused research into these factors will help clarify underlying determinants of TNBC in India. A first step in this direction would

be to institute a prospectively managed, population-based database of patients with breast cancer, along with reliable histopathologic testing.

In conclusion, this systematic review and meta-analysis demonstrated a high prevalence rate of TNBC in India. Further research to identify the

determinants of such a high prevalence of TNBC is warranted as they may have implications for addressing the burden of breast cancer mortality in India.

DOI: [10.1200/JGO.2016.005397](https://doi.org/10.1200/JGO.2016.005397)

Published online on ascopubs.org/journal/jgo on June 29, 2016.

AUTHOR CONTRIBUTIONS

Conception and design: Gurprataap S. Sandhu, Aju Mathew

Collection and assembly of data: Gurprataap S. Sandhu, Heidi Patterson, Aju Mathew

Data analysis and interpretation: Gurprataap S. Sandhu, Sebat Erqou, Aju Mathew

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted.

I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Gurprataap S. Sandhu

No relationship to disclose

Sebat Erqou

No relationship to disclose

Heidi Patterson

No relationship to disclose

Aju Mathew

No relationship to disclose

REFERENCES

1. Foulkes WD, Smith IE, Reis-Filho JS: Triple-negative breast cancer. *N Engl J Med* 363:1938-1948, 2010
2. Boyle P: Triple-negative breast cancer: Epidemiological considerations and recommendations. *Ann Oncol* 23 (suppl 6):vi7-vi12, 2012
3. Brewster AM, Chavez-MacGregor M, Brown P: Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. *Lancet Oncol* 15:e625-e634, 2014
4. Bauer KR, Brown M, Cress RD, et al: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California Cancer Registry. *Cancer* 109:1721-1728, 2007
5. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. *JAMA* 295:2492-2502, 2006
6. Fitzmaurice C, Dicker D, Pain A, et al: The global burden of cancer 2013. *JAMA Oncol* 1:505-527, 2015 [Erratum: *JAMA Oncol* 1:690, 2015]
7. International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
8. Allemani C, Weir HK, Carreira H, et al: Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet* 385:977-1010, 2015
9. Khokhar A: Breast cancer in India: Where do we stand and where do we go? *Asian Pac J Cancer Prev* 13:4861-4866, 2012
10. Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. *Mod Pathol* 21:S8-S15, 2008 (suppl 2)
11. Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. *Lancet* 378:771-784, 2011
12. Wolff AC, Hammond MEH, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Arch Pathol Lab Med* 131:18-43, 2007
13. Vandembroucke JP, von Elm E, Altman DG, et al: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. *Ann Intern Med* 147:W163-W194, 2007
14. Verma S, Bal A, Joshi K, et al: Immunohistochemical characterization of molecular subtypes of invasive breast cancer: A study from North India. *APMIS* 120:1008-1019, 2012
15. Nigam JS, Yadav P, Sood N: A retrospective study of clinico-pathological spectrum of carcinoma breast in a West Delhi, India. *South Asian J Cancer* 3:179-181, 2014

16. Nabi MG, Ahangar A, Wahid MA, et al: Clinicopathological comparison of triple negative breast cancers with non-triple negative breast cancers in a hospital in North India. *Niger J Clin Pract* 18:381-386, 2015
17. Doval DC, Sharma A, Sinha R, et al: Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. *Asian Pac J Cancer Prev* 16:4959-4964, 2015
18. Sen S, Gayen R, Das S, et al: A clinical and pathological study of triple negative breast carcinoma: Experience of a tertiary care centre in eastern India. *J Indian Med Assoc* 110:686-689, 705, 2012
19. Nandi M, Mahata A, Mallick I, et al: Hypofractionated radiotherapy for breast cancers–Preliminary results from a tertiary care center in eastern India. *Asian Pac J Cancer Prev* 15:2505-2510, 2014
20. Jana D, Sarkar DK, Ganguly S, et al: Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer? *Indian J Surg Oncol* 5:282-289, 2014
21. Sharma M, Sharma JD, Sarma A, et al: Triple negative breast cancer in people of North East India: Critical insights gained at a regional cancer centre. *Asian Pac J Cancer Prev* 15:4507-4511, 2014
22. Singh R, Gupta S, Pawar SB, et al: Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. *J Cancer Res Ther* 10:26-28, 2014
23. Akhtar M, Dasgupta S, Rangwala M: Triple negative breast cancer: An Indian perspective. *Breast Cancer (Dove Med Press)* 7:239-243, 2015
24. Mane A, Khatib KI, Deshmukh SP, et al: A comparison of clinical features, pathology and outcomes in various subtypes of breast cancer in Indian women. *J Clin Diagn Res* 9:PC01-PC04, 2015
25. Ghosh J, Gupta S, Desai S, et al: Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. *Indian J Cancer* 48:391-396, 2011
26. Zubeda S, Kaipa PR, Shaik NA, et al: Her-2/neu status: A neglected marker of prognostication and management of breast cancer patients in India. *Asian Pac J Cancer Prev* 14:2231-2235, 2013
27. Patnayak R, Jena A, Rukmangadha N, et al: Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. *Indian J Med Paediatr Oncol* 36:117-122, 2015
28. Rao C, Shetty J, Kishan Prasad HL: Morphological profile and receptor status in breast carcinoma: An institutional study. *J Cancer Res Ther* 9:44-49, 2013
29. Ambroise M, Ghosh M, Mallikarjuna VS, et al: Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. *Asian Pac J Cancer Prev* 12:625-629, 2011
30. Lakshmaiah KC, Das U, Suresh TM, et al: A study of triple negative breast cancer at a tertiary cancer care center in southern India. *Ann Med Health Sci Res* 4:933-937, 2014
31. Trivers KF, Lund MJ, Porter PL, et al: The epidemiology of triple-negative breast cancer, including race. *Cancer Causes Control* 20:1071-1082, 2009
32. Amirikia KC, Mills P, Bush J, et al: Higher population-based incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. *Cancer* 117:2747-2753, 2011
33. Stead LA, Lash TL, Sobieraj JE, et al: Triple-negative breast cancers are increased in black women regardless of age or body mass index. *Breast Cancer Res* 11:R18, 2009
34. Stark A, Kleer CG, Martin I, et al: African ancestry and higher prevalence of triple-negative breast cancer: Findings from an international study. *Cancer* 116:4926-4932, 2010

APPENDIX

Fig A1 –
Funnel plot with pseudo
95% CIs. TNBC, triple-
negative breast cancer.